RP
Royalty Pharma
RPRX · NASDAQ
$58.75 -2.73% (-$1.65)
1M -0.79%
Market Cap $26.0B
P/E Ratio 31.94x
Div. Yield 1.57%
ROE 12.25%
Bulios Fair Price
$29.43
49.9% downside
Trenutna cena
$58.75
Podcenjeno Poštena vrednost Precenjeno
Po podatkih Bulios Fair Price je delnica RPRX trenutno precenjena glede na svojo tržno ceno. Kako deluje?
Bulios Fair Price je ocena poštene vrednosti delnice iz Buliosovega modela vrednotenja. Je vhod za vašo lastno analizo, ne naložbeno priporočilo. Kako deluje?
Piotroski F-Score Moderate
6/9Valuation
46 /100
Fair EV/EBITDA 19.93x
P/S 10.27x
P/B 3.81x
Growth
57 /100
Stable Rev. growth 2.06%
FCF growth 5.11%
Book val. growth 4.79%
Profitability
100 /100
Strong Net margin 32.15%
Op. margin 62.34%
FCF margin 117.37%
Quality
43 /100
Average ROE 12.25%
ROA 4.11%
Asset turnover 0.13x
Debt
36 /100
Moderate Current ratio 1.29x
Int. coverage 4.74x
Net debt/EBITDA 4.75x
Stability
59 /100
Moderate Rev. volatility 5.21%
EPS volatility 1,411.73%
Profitable years 6
Bulios Scoring opisuje kakovost in preteklost podjetja, ne prihodnjega donosa. Visok rezultat ni nakupni signal. Izvedite več
Vprašajte StockBota o RPRX
Online
Sector
Healthcare
Industry
Medical - Pharmaceuticals
CEO
Pablo Legorreta
Employees
100
Headquarters
New York
Prihajajoči dogodki
04 NOV.
Earnings
Upcoming earnings report